Management of Left Ventricular Hypertrophy with Strain Pattern

Initial Assessment & Risk Stratification

The presence of an ECG strain pattern (down‑sloping ST depression with inverted T‑waves in V5‑V6) signals significant anatomic LVH and mandates immediate antihypertensive therapy rather than observation. 1, 2

ACE inhibitors are the preferred initial agents for most patients with LVH, with dose titration to levels proven effective in clinical trials. 1, 3, 2
Angiotensin‑receptor blockers (ARBs) are recommended when ACE inhibitors are not tolerated; they provide LVH regression comparable to ACE inhibitors and reduce LV mass more effectively than β‑blockers. 1, 3, 2, 4
Long‑acting dihydropyridine calcium‑channel blockers (e.g., amlodipine) constitute an alternative first‑line option and have demonstrated efficacy in LVH regression. 1, 3, 2, 3
Thiazide or thiazide‑like diuretics (especially chlorthalidone) can be used as initial therapy; chlorthalidone shows modest superiority for LVH reduction. 1, 3, 2, 4
Direct arterial vasodilators such as hydralazine and minoxidil should be avoided in the management of LVH. 1, 3, 2

Aim for a minimum blood‑pressure goal of <140/90 mmHg, with a stricter target of <130/80 mmHg when tolerated. 3, 2
During titration of renin‑angiotensin system (RAS) blockers, regularly monitor serum potassium and creatinine to detect hyperkalaemia or renal impairment. 4

If monotherapy fails to achieve target BP or LVH regression, add a thiazide diuretic to an ACE inhibitor or ARB. 1, 3
For additional BP control, add a dihydropyridine CCB to the existing regimen. 1, 5
An ARB may be combined with an ACE inhibitor only with careful surveillance for hypotension, hyperkalaemia, and renal dysfunction; this combination is not advised in certain groups (e.g., post‑stroke patients). 1, 5, 3

Severe hypertension with mild, symmetric ventricular thickening favors a diagnosis of hypertensive heart disease rather than HCM. 6
Mild hypertension accompanied by asymmetric or markedly severe wall thickness (>18 mm) suggests HCM. 6
When HCM is suspected, β‑blockers or non‑dihydropyridine CCBs become the first‑line therapeutic agents. 7

Echocardiography should be performed to quantify LV mass, evaluate for diastolic or systolic dysfunction, and monitor true LVH regression (since strain‑pattern regression mirrors BP decline but is not a surrogate for LV mass change). 8, 4
Medication adherence should be assessed regularly; simplifying regimens to once‑daily dosing improves compliance. 3, 5
Repeat echocardiography at 6–12 months to document LVH regression. 8

Prompt initiation of appropriate antihypertensive agents and aggressive BP control substantially reduce cardiovascular morbidity and mortality in patients with LVH and strain pattern. 1, 2